September 16
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Institute for Innovation in Biotechnology (IIB) works in close association with the School of Biological Sciences (SBS) at the University of Auckland, and focuses on industry partnerships to accelerate innovation and develop new models of bioscience enterprise training.
ViewMaking translatable molecular discoveries.
ViewAlfred Health is a leader in health care delivery, improvement, research and education. It strives to achieve best possible health outcomes for patients and the community by integrating clinical practice with research and education.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreCerta Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Read moreBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.
Read moreENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Read moreNRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Read more